GlucoTrack to be delisted from Nasdaq after missing bid price deadline
Nasdaq will suspend trading in GlucoTrack's common stock on October 30, 2026, after the company failed to maintain a $1.00 closing bid price through its compliance deadline.
GlucoTrack, Inc. disclosed in an 8-K dated October 28, 2026 that it received written notice from a Nasdaq Hearings Panel determining to delist the company's securities. The company had previously received a determination from Nasdaq to delist its securities for failure to comply with the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).1 Following a hearing, the Panel had granted GlucoTrack an exception to regain compliance, conditioned on maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026.1
On October 28, 2026, the company received written notice from the Panel that it had determined to delist GlucoTrack's securities because the closing bid price was $0.87 on October 14, 2026, meaning the company did not satisfy the terms of the exception.1
Trading in GlucoTrack's common stock on Nasdaq will be suspended at the open of trading on October 30, 2026.1 The company expects Nasdaq to file a Form 25 with the SEC to delist the securities and deregister them under Section 12(b) of the Securities Exchange Act of 1934.1
GlucoTrack said it expects and plans for its common stock to be quoted by the OTC Markets Group upon suspension from Nasdaq trading, and it intends to apply to have its securities traded on the OTCID Market.1
The filing was signed by Erik Emerson, Chief Executive Officer, on October 29, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.